How it works
Inhibits nicotinamide N-methyltransferase (NNMT), an enzyme overexpressed in obese adipose tissue. Blocking it raises intracellular NAD+ and SAM, increasing energy expenditure in fat cells.
Structure: Small molecule (not strictly a peptide)
Reported benefits
- Reduced fat-cell size in rodent studies
- Increased cellular NAD+
- Oral bioavailability — no injections
Practical considerations
- No published human trials
- Often stacked with metabolic peptides
- Marketed heavily ahead of the evidence
Side effects and risks
- Insomnia if dosed late
- Mild GI upset
- Unknown long-term profile
5-Amino-1MQ dosing overview
50–150 mg once daily in the morning
| Context | Amount | Frequency | Route |
|---|---|---|---|
| Commonly cited protocol | 50–150 mg | Once daily, morning | Oral capsule |
This describes doses reported in published literature and community protocols. It is not a recommendation, and it is not a substitute for clinical supervision.
5-Amino-1MQ FAQ
What does 5-Amino-1MQ do?
It inhibits NNMT, an enzyme in adipose tissue that consumes NAD+ precursors. Blocking it raises cellular NAD+ and, in mice, reduced fat mass without changing food intake.
Is there human evidence?
No published human trial exists. All efficacy claims trace back to rodent and cell work.
Is it a supplement?
No. It is a research compound and does not meet the definition of a dietary ingredient, despite being sold in capsule form.
Research references
- Neelakantan et al., 2018 — NNMT inhibitor in diet-induced obese mice